Q-omics provides the consensus-scored MYCT1 profile across patient tissues and cancer cell-line models. MYCT1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYCT1 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, MYCT1 protein abundance shows 30,758 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where MYCT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYCT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYCT1 survival associations across molecular data types. MYCT1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYCT1 RNA expression–survival associations across cancer types. High MYCT1 expression shows unfavorable associations in KIRP, MESO, UVM, LUSC and STAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYCT1 RNA expression.
This table summarizes MYCT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYCT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYCT1 shows lower tumor expression in LUAD, KICH, BLCA, THCA, LUSC and KIRP. The LUAD box plot shows higher MYCT1 RNA expression in normal versus tumor tissue (log2 FC = −2.402, t-test p < 0.001).
This table shows molecular features associated with MYCT1 in patient tissues and cancer cell lines. In patient samples, MYCT1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYCT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
